ArticleNPJ Parkinson's disease2025
Impulsive-compulsive behaviours and striatal neuroactivity in mildly parkinsonian rats under D2/3 agonist and L-DOPA treatment.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cariprazine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder: A case report.Biomedical reports · 2026Article
- The Effect of Dopaminergic Medication on Impulse Control and Compulsive Behaviour: A Translational Perspective.Basic & clinical pharmacology & toxicology · 2026Review
- Indirect Striatal Projection Neurons Drive a D2 Receptor-Dependent Pathway to Dyskinesia and Dystonia.Movement disorders : official journal of the Movement Disorder Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Dopamine replacement therapy for Parkinson's disease can induce impulsive-compulsive behaviours (ICBs). Here we compare the D2/3 agonist ropinirole and L-DOPA, given alone or combined, with regard to their potential to induce ICBs in rats sustaining bilateral striatal injections of 6-hydroxydopamine. Daily treatment with ropinirole (2.5 mg/kg), L-DOPA (24.0 mg/kg), or their combination was given for six weeks while animals were examined using tests of compulsive checking and motor stereotypies not previously used in the ICB literature. Independently of L-DOPA cotreatment, ropinirole induced a stereotyped hyperactivity pattern, compulsive checking, and maladaptive choices in the rat version of the Iowa gambling task. Compared to both L-DOPA and vehicle, ropinirole elicited a distinct pattern of striatal neuroactivity, shifting the expression of a cellular activity marker from dorsolateral to centro-medial regions. Our results reveal quite distinct profiles of ICBs and striatal activation upon treatment with ropinirole or L-DOPA, providing clues of therapeutic relevance to Parkinson's ICBs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.